In the last half of the century, advances in the systemic therapy of cancer, including
chemotherapy, hormonal therapy, targeted therapy, and immunotherapy have been …

Importance of the field: A concerted effort by the pharmaceutical industry over the last
decade has led to the successful clinical development of protein kinase inhibitors as …

The drug–drug interaction (DDI) potential of tyrosine kinase inhibitors (TKI) as interacting
drugs via transporter inhibition has not been fully assessed. Here, we estimated the half …

Hyperlactatemia and lactic acidosis are two syndromes that are associated with morbidity
and mortality. Medication‐induced hyperlactatemia and lactic acidosis are diagnoses of …

Simple Summary This review reports the risk and management of the hepatotoxicity of all the
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …

Drug-induced liver injury (DILI) due to chemotherapeutic drugs is a significant cause of
morbidity and mortality. Most cases of chemotherapy-induced hepatotoxicity are …

Liver ailments have become one of the most health-threatening problems, looking for safe
and effective natural liver protection agents is one of future directions. Flavonoids are widely …

Significance: Cancer-associated tissue-specific lactic acidosis stimulates and mediates
tumor invasion and metastasis and is druggable. Rarely, malignancy causes systemic lactic …

Abstract Introduction and Objectives There is increasing evidence to suggest that
therapeutic doses of metformin are unlikely to cause lactic acidosis. The aims of this …

The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (ERL) is approved for
treatment of non–small-cell lung cancer. Numerous reports of ERL-associated toxicities are …